Novel Mechanism of Resistance to Venetoclax Identified in CLL, Lymphoma - AJMC.com Managed Markets Network

Researchers have found that resistance to the BCL2 inhibitor was driven by methylation and epigenetic silencing of PUMA.

Findings from a new study show a probable driver behind resistance to venetoclax in patients with aggressive lymphoma or high-risk chronic lymphocytic leukemia (CLL). The researchers, who used whole… [+3256 chars]

full article...